UPDATE 1-Dendreon files in U.S. for prostate cancer vaccine

* Had previously said would seek OK in November

* Shares rise 4.8 pct

NEW YORK, Nov 2 - Dendreon Corp has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said on Monday, sending shares higher.

Dendreon previously said it expected to seek U.S. approval for Provenge in November and that it expected regulators to respond by mid-2010.

If approved, Provenge would be the first "therapeutic" cancer vaccine. While conventional vaccines prevent disease, Provenge treats the condition.

"With the (application) submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," Dendreon Chief Executive Mitchell Gold said in a statement.

Dendreon shares, which have soared 10-fold since March, were up 4.8 percent at $26.48 in premarket trading.